Diampa 25

Presentation: Tablets containing 25 mg empagliflozin.

Indications: Indicated in adults with type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise. Also indicated to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.  

Dosage and Administration:The recommendedstarting dose is 10 mg once daily. The dose may be increased to 25 mg once daily in patients who are tolerating 10 mg and need additional glycemic control. Can be taken with or without food. Assess renal function before initiation and periodically thereafter. Not recommended for use in patients with eGFR less than 30 mL/min/1.73 m². Follow physician's instructions.

Side Effects: Common side effects include urinary tract infections and female genital mycotic infections. Increased urination and thirst may occur due to its mechanism of action. Less common but potentially serious side effects include diabetic ketoacidosis (more likely in patients with type 1 diabetes or other risk factors) and acute kidney injury.

Precautions: Not recommended for use in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or end-stage renal disease. Use with caution in patients with moderate renal impairment (eGFR 30 to < 60 mL/min/1.73 m²), those at risk for volume depletion (e.g., elderly patients, those on diuretics), and patients with a history of urinary tract infections. Monitor for signs and symptoms of ketoacidosis.

Storage: Store below 30°C, in a dry place, protected from light and moisture. Keep out of reach of children.

Important Note: This information is for general knowledge only, not medical advice. Consult your doctor or pharmacist for specific guidance.